N
8.97
0.32 (3.70%)
| Penutupan Terdahulu | 8.65 |
| Buka | 8.91 |
| Jumlah Dagangan | 53,432 |
| Purata Dagangan (3B) | 58,403 |
| Modal Pasaran | 218,588,128 |
| Harga / Jualan (P/S) | 3.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| Margin Operasi (TTM) | -93,965.52% |
| EPS Cair (TTM) | -2.47 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -7.00% |
| Nisbah Semasa (MRQ) | 0.410 |
| Aliran Tunai Operasi (OCF TTM) | -10.01 M |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | NeOnc Technologies Holdings, In | - | - |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.00% |
| % Dimiliki oleh Institusi | 0.31% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Westmount Partners, Llc | 31 Dec 2025 | 43,320 |
| Hcr Wealth Advisors | 31 Dec 2025 | 15,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |